Polygenic Risk Score Reveals Genetic Heterogeneity of Alzheimer’s Disease between the Chinese and European Populations - 21/11/24

Doi : 10.14283/jpad.2024.29 
F. Li 1, S. Xie 1, J. Cui 1, Y. Li 1, T. Li 1, Y. Wang 1, Jianping Jia 1, 2, 3, 4, 5,
1 Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Changchun Street 45, Xicheng District, Beijing, P.R. China 
2 Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, P.R. China 
3 Clinical Center for Neurodegenerative Disease and Memory Impairment, Capital Medical University, Beijing, P.R. China 
4 Center of Alzheimer’s Disease, Beijing Institute of Brain Disorders, Collaborative Innovation Center for Brain Disorders, Capital Medical University, Beijing, P.R. China 
5 Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, P.R. China 

g jiajp@vip.126.com jiajp@vip.126.com

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Background

The polygenic risk score (PRS) aggregates the effects of numerous genetic variants associated with a condition across the human genome and may help to predict late-onset Alzheimer’s disease (LOAD). Most of the current PRS studies on Alzheimer’s disease (AD) have been conducted in Caucasian ancestry populations, while it is less studied in Chinese.

Objective

To establish and examine the validity of Chinese PRS, and explore its racial heterogeneity.

Design

We constructed a PRS using both discovery (N = 2012) and independent validation samples (N = 1008) from Chinese population. The associations between PRS and age at onset of LOAD or cerebrospinal fluid (CSF) biomarkers were assessed. We also replicated the PRS in an independent replication cohort with CSF data and constructed an alternative PRS using European weights.

Setting

Multi-center genetics study.

Participants

A total of 3020 subjects were included in the study.

Measurements

PRS was calculated using genome-wide association studies data and evaluated the performance alone (PRSnoAPOE) and with other predictors (full model: LOAD ∼ PRSnoAPOE + APOE+ sex + age) by measuring the area under the receiver operating curve (AUC).

Results

PRS of the full model achieved the highest AUC of 84.0% (95% CI = 81.4–86.5) with pT< 0.5, compared with the model containing APOE alone (61.0%). The AUC of PRS with pT< 5e–8 was 77.8% in the PRSnoAPOE model, 81.5% in the full model, and only ranged from 67.5% to 75.1% in the PRS with the European weights model. A higher PRS was significantly associated with an earlier age at onset (P <0.001). The PRS also performed well in the replication cohort of the full model (AUC=83.1%, 95% CI = 74.3–92.0). The CSF biomarkers of Aβ42 and the ratio of Aβ42/Aβ40 were significantly inversely associated with the PRS, while p-Tau181 showed a positive association.

Conclusions

This finding suggests that PRS reveal genetic heterogeneity and higher prediction accuracy of the PRS for AD can be achieved using a base dataset and validation within the same ethnicity. The effective PRS model has the clinical potential to predict individuals at risk of developing LOAD at a given age and with abnormal levels of CSF biomarkers in the Chinese population.

Le texte complet de cet article est disponible en PDF.

Key words : Genetic, polygenic risk score, late-onset Alzheimer’s disease, prediction, biomarker


Plan


© 2024  THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 11 - N° 3

P. 701-709 - mai 2024 Retour au numéro
Article précédent Article précédent
  • Cognitive Training with Older Adults Using Smartphone and Web-Based Applications: A Scoping Review
  • A.F. Silva, Rui Miguel Silva, E. Murawska-Ciałowicz, G. Zurek, N. Danek, M. Cialowicz, J. Carvalho, F.M. Clemente
| Article suivant Article suivant
  • Longitudinal Impacts of Precision Greenness on Alzheimer’s Disease
  • S.C. Brown, W.W. Aitken, J. Lombard, A. Parrish, J.R. Dewald, R. Ma, S. Messinger, S. Liu, M.I. Nardi, T. Rundek, J. Szapocznik

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.